Protagonist Reports Q4/FY25 Loss, Plans Rusfertide Profit-Sharing Opt-Out, and Extends Cash Runway
PTGX has more than doubled off its 52-week low of $33.7 on light trading volume (0.4× avg).
Summary
Protagonist Therapeutics reported a net loss for Q4 and FY2025 but announced plans to opt-out of its rusfertide profit-sharing agreement, signaling high confidence in the drug, and confirmed a strong cash runway through 2028.
Key Events · Earnings and Guidance · PTGX
-
Q4 and Full Year 2025 Financial Results
The company reported a net loss of $44.4 million for Q4 2025 and $130.1 million for the full year 2025, a significant decrease from net income in the prior year. License and collaboration revenue also saw a substantial decline.
-
Strategic Opt-Out for Rusfertide
Protagonist expects to exercise its right to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda in Q2 2026, indicating strong confidence in the drug's commercial prospects and a move to capture a larger share of future profits.
-
Key Regulatory Milestones
The New Drug Application (NDA) for rusfertide has been submitted to the FDA, with potential approval and launch anticipated this year. A U.S. regulatory decision for ICOTYDE™ (icotrokinra) is also expected in 2026, with a potential launch this year if approved.
-
Strong Cash Position and Runway
Cash, cash equivalents, and marketable securities totaled $646.0 million as of December 31, 2025, which is anticipated to provide a cash runway through at least the end of 2028.
Analysis · PTGX · Life Sciences
Protagonist Therapeutics reported a significant net loss for both the fourth quarter and full year 2025, alongside a substantial decrease in revenue compared to the prior year. However, the filing also contains highly material strategic updates. The company plans to opt-out of its 50:50 profit and loss sharing arrangement for rusfertide with Takeda, signaling strong confidence in the drug's commercial potential and a move to capture full value. Additionally, the company anticipates a U.S. regulatory decision for ICOTYDE™ in 2026 and has expanded its preclinical pipeline. A robust cash position of $646 million provides a runway through at least the end of 2028, significantly de-risking the company's financial outlook despite current losses. Investors should monitor the rusfertide opt-out process and upcoming regulatory decisions for ICOTYDE™ and rusfertide, as these are critical for future revenue generation.
At the time of this filing, PTGX was trading at $87.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $33.70 to $96.54. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.